Macro Group Pharmaceuticals (Macro Capital) S.A.E (EGX:MCRO)
Egypt · Delayed Price · Currency is EGP 1.290
-0.060 (-4.44%)
At close: Oct 22, 2026
EGX:MCRO Revenue
Macro Group Pharmaceuticals (Macro Capital) S.A.E had revenue of 302.95M EGP in the quarter ending June 30, 2026, with 33.37% growth. This brings the company's total for the last twelve months to 1.06B, up 36.32% year-over-year. In the year 2025, Macro Group Pharmaceuticals (Macro Capital) S.A.E had annual revenue of 894.54M with 72.04% growth. That makes Macro Group Pharmaceuticals (Macro Capital) S.A.E the 34,071st largest company in the world by revenue and 127th in Egypt.
Revenue (ttm)
1.06B
Revenue Growth
+36.32%
P/S Ratio
4.17
Revenue / Employee
n/a
Employees
n/a
Market Cap
4.41B
Revenue by Geography
- Egypt 863.75M 96.6%
- Export 30.80M 3.4%
Fiscal year ended Dec 31, 2025 See the full EGX:MCRO breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 894.54M | 374.58M | 72.04% |
| Dec 31, 2024 | 519.97M | -6.04M | -1.15% |
| Dec 31, 2023 | 526.01M | -203.61M | -27.91% |
| Dec 31, 2022 | 729.61M | 135.35M | 22.78% |
| Dec 31, 2021 | 594.26M | 163.76M | 38.04% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.